Multicenter Study on the Long-Term (3-Year) Efficacy of Lanthanum Carbonate in Dialysis Patients

被引：0

作者：

Ando, Ryoichi ^{[1
]}

Yama, Satomi ^{[1
]}

Ohnishi, Tsuyoshi ^{[1
]}

Iwamoto, Shunsuke ^{[1
]}

Kimura, Hitoshi ^{[1
]}

Chida, Yoshiko ^{[2
]}

Ishida, Yuji ^{[3
]}

Yamada, Kouei ^{[4
]}

Inagaki, Yuichiro ^{[4
]}

Takayama, Masanobu ^{[5
]}

Tachibana, Ken ^{[6
]}

Kikuchi, Kan ^{[7
]}

Inoue, Atsushi ^{[7
]}

Ohtsuka, Masakazu ^{[8
]}

机构：

[1] Musashino Red Cross Hosp, Dept Nephrol, Tokyo, Japan

[2] Nakano Clin, Tokyo, Japan

[3] Kyonan Clin, Tokyo, Japan

[4] Kichijoji Ekimae Clin, Tokyo, Japan

[5] Takayama Clin, Tokyo, Japan

[6] Tachibana Clin, Tokyo, Japan

[7] Shimo Ochiai Clin, Tokyo, Japan

[8] Tokiwa Clin, Toride, Ibaraki, Japan

来源：

THERAPEUTIC APHERESIS AND DIALYSIS | 2014年 / 18卷

关键词：

Lanthanum Carbonate; Long-Term Effects; Management Target Values; Multicenter Study; CHRONIC KIDNEY-DISEASE; MORTALITY RISK; SERUM-CALCIUM; HEMODIALYSIS-PATIENTS; PHOSPHATE; HYPERPHOSPHATEMIA; PTH;

D O I：

10.1111/1744-9987.12206

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We previously conducted a multicenter study enrolling 101 dialysis patients with hyperphosphatemia in which lanthanum carbonate (LC) was administered for 2 years. In this study, the administration has been continued for an additional year, and we have evaluated the long-term (a total of 3 years) effects of LC. The average serum phosphorus (P) level was 6.05 mg/dL at the start and decreased to 5.84 mg/dL after 3 years, but no significant differences were observed at both points. The average serum corrected calcium (Ca) level significantly reduced after 3 years (P < 0.001). As results of evaluating the achievement rates with the management target values of serum P, Ca and intact parathyroid hormone (PTH) stated in the Japanese guideline, the achievement rates increased after 3 years. From these results, LC is considered to be a useful P binder that can be used for long-term treatment of hyperphosphatemia, without causing a Ca load.

引用

页码：2 / 8

页数：7

共 50 条

[41] The long-term clinical impact of COPD exacerbations: a 3-year observational study (SHERLOCK)
Haughney, John
Lee, Amanda J.
Nath, Mintu
Mullerova, Hana
Holmgren, Ulf
de Nigris, Enrico
Ding, Bo
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
[42] Sustained clinical response and high infliximab survival in psoriatic arthritis patients: A 3-year long-term study
Voulgari, Paraskevi V.
Venetsanopoulou, Aliki I.
Exarchou, Sofia A.
Alamanos, Yannis
Tsifetaki, Niki
Drosos, Alexandros A.
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2008, 37 (05) : 293 - 298
[43] One-year, randomized, open-label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol®) and calcium carbonate in dialysis patients.
Torres, A
De Broe, ME
D'Haese, PC
Hutchison, A
Jones, C
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 764A - 764A
[44] Efficacy and safety of long-term treatment with lanthanum carbonate - A novel phosphate-binding agent
Finn, W
Joy, M
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) : A18 - A18
[45] Long-term efficacy and safety profile of lanthanum carbonate: Results for up to 6 years of treatment
Hutchison, Alastair J.
Barnett, M. Edwina
Krause, Rolfdieter
Kwan, Jonathan T. C.
Siami, Ghodrat A.
NEPHRON CLINICAL PRACTICE, 2008, 110 (01): : C15 - C23
[46] Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease
Hughes, Derralynn
Gonzalez, Derlis
Maegawa, Gustavo
Bernat, John A.
Holida, Myrl
Giraldo, Pilar
Atta, Mohamed G.
Chertkoff, Raul
Alon, Sari
Almon, Einat Brill
Rocco, Rossana
Goker-Alpan, Ozlem
GENETICS IN MEDICINE, 2023, 25 (12)
[47] Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: Analysis of a European, multinational, multicenter, open-label study
Schulman, CC
Cortvriend, J
Jonas, U
Lock, TMTW
Vaage, S
Speakman, MJ
EUROPEAN UROLOGY, 1999, 36 (06) : 609 - 620
[48] Further evidence for the long-term safety and tolerability of lanthanum carbonate
Siami, G
Backs, W
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) : A48 - A48
[49] Long-term Efficacy and Safety of Fingolimod in Japanese Patients with Relapsing Multiple Sclerosis (MS): 3-year Results from a Phase 2 Extension Study
Kira, J.
Itoyama, Y.
Kikuchi, S.
Hao, Q.
Kurosawa, T.
Ueda, K.
Nagato, K.
Saida, T.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 928 - 929
[50] Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
Trauner, Michael
Nevens, Frederik
Shiffman, Mitchell L.
Drenth, Joost P. H.
Bowlus, Christopher L.
Vargas, Victor
Andreone, Pietro
Hirschfield, Gideon M.
Pencek, Richard
Malecha, Elizabeth Smoot
MacConell, Leigh
Shapiro, David
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (06): : 445 - 453

← 1 2 3 4 5 →